Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: A hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Puig Barberà, Joan ^a,b   García De Lomas, Juan ^c   Díez Domingo, Javier ^a   Arnedo Pena, Alberto ^b   Ruiz García, Montserrat ^b   Limón Ramírez, Ramón ^d   Pérez Vilar, Silvia ^d   Micó Esparza, José Luis ^e   Tortajada Girbés, Miguel ^f   Carratalá Munuera, Concha ^g,h   Larrea González, Rosa ⁱ   Beltrán Garrido, Juan Manuel ⁱ   Otero Reigada, Maria Del Carmen ^j   Mollar Maseres, Joan ^j   Correcher Medina, Patricia ^k   Schwarz Chavarri, Germán ^l   Gil Guillén, Vicente ^h,m   Valencia Hospital Network for the Study of Influenza and Respiratory Virus Disease, ⁿ  

^a Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la Comunitat Valenciana   (Spain)

^b Centro de Salud Publica de Castellon   (Spain)

^c Instituto Valenciano de Microbiologia   (Spain)

^d HOSPITAL DE LA PLANA   (Spain)

^e Hospital Aranau de Vilanova   (Spain)

^f HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^g HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^h MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

ⁱ HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k HOSPITAL LLUÍS ALCANYÍS   (Spain)

^l Centro de Salud San Blas   (Spain)

^m Hospital de Elda   (Spain)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; COMORBIDITY; DRUG EFFICACY; EMERGENCY CARE; FEMALE; FLU LIKE SYNDROME; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SPAIN; VERY ELDERLY; VIRUS DETECTION; YOUNG ADULT; ADOLESCENT; COMPARATIVE EFFECTIVENESS; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPAIN; YOUNG ADULT;

EID: 84911487300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112294     Document Type: Article

References (50)

1. Bloom-Feshbach K, Alonso WJ, Charu V, Tamerius J, Simonsen L, et al. (2013) Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One 8: e54445.
2. Olson DR, Heffernan RT, Paladini M, Konty K, Weiss D, et al. (2007) Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med 4: e247.
3. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, et al. (2012) Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 54: 1427-1436.
4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
5. World Health Organization (2012) Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 87: 461-476.
6. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852-6862.
7. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, et al. (2009) Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 199: 159-167.
8. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2011) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36-44.
9. Katz JM, Webster RG (1989) Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 160: 191-198.
10. Rocha EP, Xu X, Hall HE, Allen JR, Regnery HL, et al. (1993) Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J Gen Virol 74 (Pt 11): 2513-2518.
11. Ndifon W, Wingreen NS, Levin SA (2009) Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A 106: 8701-8706.
12. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, et al. (2014) Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 9: e92153.
13. Puig-Barberà J, Natividad-Sancho A, Launay O, Burtseva E, Ciblak MA, et al. (2014) 2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network. PLoS One 9: e100497.
14. Maciosek MV, Edwards NM, Coffield AB, Flottemesch TJ, Nelson WW, et al. (2006) Priorities among effective clinical preventive services: methods. Am J Prev Med 31: 90-96.
15. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, et al. (2009) Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 200: 492-500.
16. Rothman KJ, Greenland S, Lash TL (2008) Case-Control Studies. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. pp. 111-127.
17. Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, et al. (2010) Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine 28: 7460-7467.
18. Puig-Barberà J, Díez-Domingo J, Arnedo-Pena A, Ruiz-García M, Pérez-Vilar S, et al. (2012) Effectiveness of the 2010-2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: A case-case comparison, case-control study. Vaccine 30: 5714-5720.
19. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, et al. (2007) Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 36: 623-631.
20. De Serres G, Skowronski DM, Ambrose C (2013) The test-negativee design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical. Eurosurveillance 18: pii = 20585.
21. Jackson ML, Nelson JC (2013) The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31: 2165-2168.
22. Foppa IM, Haber M, Ferdinands JM, Shay DK (2013) The case test-negative design for studies of the effectiveness of seasonal influenza vaccine. Vaccine 31: 3104-3109.
23. Portero-Alonso A, Pastor-Villalba E, Martín-Ivorra R, Alguacil-Ramos AM, López-Maside A, et al. (2012) Prevención y vigilancia de la gripe en la Comunitat Valenciana. Temporada 2011-2012. Informe 135. Conselleria de Sanitat. Dirección General de Investigación y Salud Pública. Available: http://www.sp.san.gva.es/biblioteca/publicacion-dgsp.jsp?cod-pub-ran=709064217&tacc=15. Accessed 2013 May 10.
24. European Influenza Surveillance Network (EISN) website. Influenza case definitions. Clinical criteria. Influenza-like illness (ILI). European Centre for Disease Prevention and Control (ECDC) 2005-22012. Available: http://ecdc.europa.eu/en/activities/surveillance/EISN/surveillance/Pages/influenza-case-definitions.aspx. Accessed: 2012 Nov 2.
25. Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D (2004) Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23: 283-289.
26. Benach J, Amable M (2004) [Social classes and poverty]. Gac Sanit 18 Suppl 1: 16-23.
27. Regidor E, Grupo de Trabajo de la SEE (2001) The Goldthorpe Social Class Classification: reference framework for a proposal for the measurement of social class by the Working Group of the Spanish Society of Epidemiology. Rev Esp Salud Publica 75: 13-22.
28. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35: 337-344.
29. Jackson LA, Nelson JC, Benson P, Neuzil KM, Reid RJ, et al. (2006) Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 35: 345-352.
30. Nelson JC, Jackson ML, Weiss NS, Jackson LA (2009) New strategies are needed to improve the accuracy of influenza vaccine effectiveness estimates among seniors. J Clin Epidemiol 62: 687-694.
31. Greenland S, Robins JM (1985) Confounding and misclassification. Am J Epidemiol 122: 495-506.
32. Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, et al. (2013) Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 18: pii:20388.
33. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen J, et al. (2013) Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 18: pii = 20390.
34. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, et al. (2014) Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 58: 319-327.
35. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, et al. (2013) Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 18: pii: 20389.
36. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, et al. (2014) Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 210: 126-137.
37. Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, et al. (2013) Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis 13: 441.
38. Smith DJ, Forrest S, Ackley DH, Perelson AS (1999) Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 96: 14001-14006.
39. Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, et al. (2012) Cross-reactive and Vaccine-Induced Antibody to an Emerging Swine-Origin Variant of Influenza A Virus Subtype H3N2 (H3N2v). J Infect Dis 206: 1852-1861.
40. Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, et al. (2013) Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Adults, 2011-2012 Influenza Season. Clin Infect Dis 56: 1774-1777.
41. Bonmarin I, Belchior E, Le Strat Y, Levy-Bruhl D (2012) First estimates of influenza vaccine effectiveness among severe influenza cases, France, 2011/12. Euro Surveill 17.
42. Turner N, Pierse N, Bissielo A, Huang QS, Baker MG, et al. (2014) The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. Vaccine.
43. Thomas HL, Andrews N, Green HK, Boddington NL, Zhao H, et al. (2014) Estimating vaccine effectiveness against severe influenza in England and Scotland 2011/2012: applying the screening method to data from intensive care surveillance systems. Epidemiol Infect 142: 126-133.
44. Cheng AC, Brown S, Waterer G, Holmes M, Senenayake S, et al. (2013) Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2012: the Influenza Complications Alert Network (FluCAN). Commun Dis Intell Q Rep 37: E246-E252.
45. World Health Organization (2013) Review of the 2012-2013 winter influenza season, northern hemisphere. Wkly Epidemiol Rec 88: 225-232.
46. Delgado-Sanz C, Jiménez-Jorge S, López-Perea N, Pozo F, Gómez-Barroso D, et al. (2013) Vigilancia de la gripe en España. Temporada 2011-12 (desde la semana 40/2011 hasta la semana 20/2012). Boletín Epidemiológico Semanal 20: 153-167.
47. World Health Organization (2012) Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Wkly Epidemiol Rec 87: 83-95.
48. Legrand J, Vergu E, Flahault A (2006) Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24: 6605-6611.
49. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, et al. (2013) AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 13: 485-496.
50. World Health Organization (2013) Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season. Wkly Epidemiol Rec 88: 101-114.